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Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors reduce serum low-density 
lipoprotein cholesterol (LDL-C) by increasing up-take in the liver1. While some long-term trials 
have evaluated their safety, broad investigations of outcomes over the life-time, leveraging 
genetic variation in serum PCSK9, have seldomly been conducted. We investigated effects of 
these variants on a range of outcomes to explore unanticipated effects of long-term PCSK9 
inhibition. 
 
We linked genotype and phenotype data from 69,422 participants in the population-based Nord-
Trøndelag Health Study (HUNT) with hospital records. Coronary heart disease, myocardial 
infarction, heart failure, venous thrombosis, diabetes, asthma, chronic obstructive pulmonary 
disease, allergic rhinitis and mood disorders were indicated by ICD-9 or ICD-10 codes recorded 
between September 1987 and March 2016 or self-report in HUNT2 (1995-1997) or HUNT3 
(2006-2008). Using self-report in HUNT, we assessed anxiety, depression, musculoskeletal pain, 
headaches, pain or stiffness in muscles or joints in at least 3 consecutive months during the last 
year, gastrointestinal pain, pain in either leg while walking and pain in the legs while at rest. 
 
Blood pressure, height, weight and lung function were measured in HUNT by trained nurses or 
technicians. Non-fasting serum levels of total cholesterol, high-density lipoprotein cholesterol 
(HDL-C), triglycerides, glucose and C-reactive protein were measured, and LDL-C was 
calculated. All-cause mortality was updated from the National Population Registry. 
 
Serum concentrations of PCSK9 were measured in a sub-sample by enzyme immune-assay with 
antibodies obtained from R&D Systems (Minneapolis, Minnesota) as described elsewhere2. 
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Because of the sensitive nature of the data, requests to access the dataset from qualified 
researchers may be sent to HUNT (www.ntnu.edu/hunt). The Regional Committee for Ethics in 
Medical Research approved the study and participants gave informed consent. 
 
We performed a genome-wide association study (GWAS) of serum PCSK9 in 3,697 adults using 
BOLT-LMM adjusted for sex, age, genotyping batch and four principal components. Serum 
PCSK9 measurements were rank-transformed to normality. The replication cohort included 
5,304 adults from the TwinGene Study recruited between 2004 and 20083. We defined a new 
genetic risk score for serum PCSK9, and regressed this and an existing score (rs11206510, 
rs2479409, rs2149041, rs2479394, rs10888897, rs7552841, rs562556) on a range of outcomes1. 
For comparision, we used LDL-C-associated variants on HMGCR (rs12916, rs17238484, rs5909, 
rs2303152, rs10066707, rs2006760), the target of statins1. The associations of PCSK9 and 
HMGCR genetic risk scores with outcomes in HUNT were assessed using linear regression for 
continuous and logistic regression for binary outcomes, adjusted for age and sex. We perfomed 
two-sample Mendelian randomization on 48 outcomes using large biobanks available in MR-
Base4.  
 
We assessed 11.67 million single nucleotide and indel variants imputed from a combined 
reference panel including 2,202 low-pass sequenced HUNT genomes and the Haplotype 
Reference Consortium panel. We identified genome-wide significant associations at two loci – 
PCSK9 and PCSK2. Three independent genome-wide significant variants were identified, the 
most strongly associated variant was rs11591147 in PCSK9 (p.R46L), which was associated with 
a 1.30 unit decrease in rank-transformed serum PCSK9 (P=2.9x10-31) per effect allele (standard 
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deviation of original PCSK9 measurements=47.5 ng/ml, interquartile range=100.6-154.9), 
followed by the intronic rs499883 in PCSK9 (β=0.19, P=2.3x10-15) and rs192265866 in PCSK2 
(β=-1.05, P=2.8x10-8) of which the two variants in PCSK9 (but not the variant in PCSK2) 
replicated in TwinGene and were used to construct a new genetic risk score for PCSK9. 
 
Our results demonstrated probable causal associations between lower serum PCSK9 and both 
lower serum LDL-C (P=2.8x10-43) and lower risk of coronary heart disease (P=8.9x10-4) (Figure 
A). As analyses within HUNT suggested associations between PCSK9 and HMGCR genetic risk 
scores and risk of venous thrombosis and asthma, respectively, we investigated associations 
using summary level data from the INVENT Consortium and GABRIEL4, 5. Neither associations 
replicated (venous thrombosis, inverse variance weighted, OR=1.38, 95% CI=0.88, 2.20; asthma, 
inverse variance weighted, OR=1.13, 95% CI=0.64, 1.98). We did not observe any other 
convincing associations across a range of cardiovascular, respiratory, mental, diabetes, or pain 
related outcomes. 
 
Utilising GWAS summary statistics and two-sample MR, the PCSK9 genetic risk score was 
associated with LDL-C, HDL-C and total cholesterol as expected (Figure B). Moreover, 
genetically decreased serum PCSK9 was associated with higher father’s age at death (β=0.04, 
95% CI=0.01, 0.08), parents age at death (β=0.05, 95% CI=0.01, 0.10) and waist-to-hip ratio 
(β=0.03, 95% CI=0.01, 0.06) (Figure B). Additionally, genetically decreased serum PCSK9 was 
associated with decreased risk of coronary heart disease (odds ratio [OR]=0.84, 95% CI=0.78, 
0.89) and myocardial infarction (OR=0.81, 95% CI=0.70, 0.93), and an increased risk of 
Alzheimer’s disease (OR=1.27, 95% CI=1.04, 1.55) (Figure B). 
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In summary, we confirmed two independent genetic variants associated with serum PCSK9, and 
causal associations of lower serum PCSK9 with lower LDL-C and reduced risk of coronary heart 
disease. Additioanally, we did not observe any other consistent unexpected associations when 
investigating a range of outcomes. The lack of association with a range of potential adverse 
outcomes is reassuring for long-term use of PCSK9 inhibitors.  
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Figure. A, The association between PCSK9 and HMGCR genetic risk scores and a range of 
continuous traits (left) and diseases or traits (right) in the Nord-Trøndelag Health Study, scaled 
to a genetic risk score-determined 0.259 mmol/L (10 mg/dL) decrease in LDL cholesterol. The 
PCSK9 genetic risk score is defined from the discovery GWAS in this study. The existing 
PCSK9 score and HMGCR score are defined and weighted using results for LDL cholesterol 
associated variants from the Global Lipids Genetics Consortium. B, The association between 
genetically determined serum PCSK9 and a range of continuous traits (Amygdala volume, Birth 
weight, Body fat, Body mass index, Caudate volume, Chronotype, Depressive symptoms, 
Father’s age at death, HDL cholesterol, Hip circumference, Hippocampus volume, Intracranial 
volume, LDL cholesterol, Mean platelet volume, Mother’s age at death, Neuroticism, Nucleus 
accumbens volume, Pallidum volume, Parents' age at death, Platelet count, Putamen volume, 
Sitting height ratio, Sleep duration, Thalamus volume, Top 1 % survival, Total cholesterol, 
Triglycerides, Waist circumference, Waist-to-hip ratio, Years of schooling) (left) and diseases or 
traits (Alcohol dependence, Alzheimer's disease, Amyotrophic lateral sclerosis, Autism, Bulimia 
nervosa, Coronary heart disease, Crohn's disease, Eczema, Inflammatory bowel disease, Lung 
adenocarcinoma, Lung cancer, Multiple sclerosis, Myocardial infarction, Rheumatoid arthritis, 
Schizophrenia, Squamous cell lung cancer, Type 2 diabetes, Ulcerative colitis) (right) in MR-
Base. The new PCSK9 genetic risk score had a r2 and F-statistics of 2.1% and 80.55 for serum 
PCSK9. 
 
CI, confidence interval; COPD, chronic obstructive pulmonary disease; BMI, body mass index; 
FEV1, forced expiratory volume in one second; FVC, forced vital capacity; HADS, Hospital 
Anxiety and Depression Scale; HDL, high-density lipoprotein; HMGCR, 3-hydroxy-3-
methylglutaryl-Coenzyme A reductase; LDL, low-density lipoprotein; OR, odds ratio; PCSK9: 
Proprotein convertase subtilisin/kexin type 9. 
